TrialThe Lancet. Oncology2014

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Joyce F Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.